Advertisement

Parasitology Research

, Volume 103, Issue 2, pp 355–362 | Cite as

Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations

  • Laura CeballosEmail author
  • Celina Elissondo
  • Laura Moreno
  • Marcela Dopchiz
  • Sergio Sánchez Bruni
  • Guillermo Denegri
  • Luis Alvarez
  • Carlos Lanusse
Original Paper

Abstract

The pharmacokinetic (PK) behaviour and clinical efficacy of albendazole (ABZ) against hydatid cysts in mice were assessed after treatment with two different ABZ pharmaceutical formulations. BalbC mice received ABZ (0.5 mg/kg) prepared either as solution or suspension (50 μg/ml) for oral administration (PK study). Blood samples were collected up to 16 h post-treatment and processed to measure ABZ/metabolites concentrations in plasma. The clinical efficacy assessment was performed in BalbC mice infected 8 months earlier with Echinococcus granulosus protoscoleces. Infected animals were allocated into three experimental treatment groups: (a) untreated control, (b) ABZ-solution treated, (c) ABZ-suspension treated. Both treated groups received ABZ (0.5 mg/kg) administered under two different therapeutic schemes: dosing every 48 h over 30 days (regimen I) or treated every 12 h during 15 days (regimen II). Experimental mice were sacrificed 12 h after treatment, and cysts were recovered, weighed and processed for transmission electron microscopy. Enhanced ABZ sulphoxide (the main ABZ metabolite) concentration profiles were measured in animals treated with the ABZ solution. Any positive clinical response was obtained after treatment every 48 h (30 days therapy). However, consistent with the observed PK results, both ABZ formulations were clinically effective in infected mice treated with a 12-h dosing interval (15 days therapy).

Keywords

Hydatid Cyst Albendazole Untreated Control Group Cystic Echinococcosis Echinococcus Granulosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This work was partially supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Agencia Nacional de Promoción Científica y Técnica (ANPCyT), both from Argentina.

References

  1. Ammann R, Eckert J (1995) Clinical diagnosis and treatment of echinococcosis in humans. In: Thompson RCA, Limbery AJ (eds) Echinococcus and hydatid disease. CAB International, Wallingford, UK, pp 441–463Google Scholar
  2. Bartoloni C, Tricerri A, Guidi L, Gambassi G (1992) The efficacy of chemotherapy with mebendazole in human cystic echinococcosis: long-term follow-up of 52 patients. Ann Trop Med Parasitol 86:249–256PubMedGoogle Scholar
  3. Castillo JA, Palomo-Canales J, García JJ, Lastres JL, Torrado JJ (1999) Preparation and characterization of albendazole b-cyclodextrin complexes. Drug Dev Ind Pharm 25:1241–1248PubMedCrossRefGoogle Scholar
  4. Ceballos L, Alvarez LI, Sanchez Bruni SF, Elissondo C, Dopchiz M, Denegri G, Torrado JJ, Lanusse CE (2006) Development of a cyclodextrin-based flubendazole formulation to control secondary echinococcosis: pharmacokinetics, hydatid cyst morphology and efficacy in mice. J Vet Pharmacol Ther 29:85–86Google Scholar
  5. Davis A, Pawlowski ZS, Dixon H (1986) Multicenter trials of benzimidazole–carbamates in human echinococcosis. Bull World Health Organ 64:383–388PubMedGoogle Scholar
  6. Davis A, Dixon H, Pawlowski ZS (1989) Multicentre clinical trials of benzimidazole carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 67:503–508PubMedGoogle Scholar
  7. Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141–159PubMedCrossRefGoogle Scholar
  8. Eckert J, Deplazes P (2004) Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 17:107–135PubMedCrossRefGoogle Scholar
  9. Elissondo C, Dopchiz M, Brasesco M, Denegri G (2004) Echinococcus granulosus: first report of microcysts formation from protoscoleces of cattle origin using the in vitro vesicular culture technique. Parasite 11:415–418PubMedGoogle Scholar
  10. Elissondo C, Ceballos L, Dopchiz M, Andresiuk V, Alvarez LI, Sánchez Bruni SF, Lanusse CE, Denegri G (2007) In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes. Parasitol Res 100:1003–1009PubMedCrossRefGoogle Scholar
  11. El-On J (2003) Benzimidazole treatment of cystic echinococcosis. Acta Trop 85:243–252PubMedCrossRefGoogle Scholar
  12. Evrard B, Chiap P, DeTullio P, Ghalmid F, Piela G, Van Heesa T, Crommen J, Losson B, Delattre L (2002) Oral bioavailability in sheep of albendazole from a suspensión and from a solution containing hydroxypropyl-b-cyclodextrin. J Control Release 85:45–50PubMedCrossRefGoogle Scholar
  13. García JJ, Bolás F, Torrado JJ (2003) Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm 250:351–358PubMedCrossRefGoogle Scholar
  14. Garcıa-Rodriguez J, Torrado JJ, Bolas F (2001) Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole–cyclodextrin complexes. Parasite 8:188–190Google Scholar
  15. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  16. Horton RJ (2003) Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol 17:205–212PubMedCrossRefGoogle Scholar
  17. Jenkins DJ, Romig T, Thompson RCA (2005) Emergence/re-emergence of Echinococcus spp.—a global update. Int J Parasitol 35:1205–1219PubMedCrossRefGoogle Scholar
  18. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S, Miyazaki K (1999) Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159–164PubMedCrossRefGoogle Scholar
  19. Lanusse CE, Prichard RK (1993) Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metab Rev 25:235–279PubMedCrossRefGoogle Scholar
  20. Menezes da Silva A (2003) Hydatid cyst of the liver—criteria for the selection of appropriate treatment. Acta Trop 85:237–242PubMedCrossRefGoogle Scholar
  21. Moro P, Schantz PM (2006) Cystic echinococcosis in the Americas. Parasitol Int 55:181–186CrossRefGoogle Scholar
  22. Pawlowski ZS, Eckert J, Vuitton DA, Ammann RW, Kern P, Craig PS et al (2001) Echinococcosis in humans: clinical aspects, diagnosis and treatment. In: Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS (eds) WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. World Organisation for Animal Health, Paris, FranceGoogle Scholar
  23. Recco P, Hornus E, Frejevus J, Micheau P, Bessieres MH, Roques C, Linas MD (1984) Hydatidose pleurale disseminee et hydatidoses hepatiquesTreatment post-operatoire par flubendazole a propos de 3 cas. Bull Soc Fr Parasitol 3:115–118Google Scholar
  24. Rippman K, Dietrich M, Kern P (1992) Long-term therapy of cystic liver echinococcosis with mebendazole. Medizin Klin 87:350–354Google Scholar
  25. Rodrigues JM, Bories C, Emery I, Fessi H, Devissaguet JP, Liance M (1995) Development of an injectable formulation of albendazole and in vivo evaluation of its efficacy against Echinococcus multilocularis metacestode. Int J Parasitol 12:1437–1441CrossRefGoogle Scholar
  26. Shuhua X, Jiqing Y, Mingjie W, Pieying J, Fanghua G, Junjie C, Wei J, Hotez P (2002) Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Trop 82:77–84PubMedCrossRefGoogle Scholar
  27. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hemphill A (2004) Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 34:615–624PubMedCrossRefGoogle Scholar
  28. Teggi A, Lastilla GM, De Rosa F (1993) Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 37:1679–1684PubMedGoogle Scholar
  29. Thompson D, Geary T (1995) The structure and function of helminth surfaces. In: Harr J, Muller M (eds) Biochemistry and molecular biology of parasites. Academic, London, UKGoogle Scholar
  30. Todorov T, Mechkov G, Georgiev P, Handjiev S, Vutova K, Petkov D et al (1998) Chemotherapy of human cystic hydatid disease: indications, effectiveness, prognosis. Mediterr J Infect Parasitic Diseases 13:89–94Google Scholar
  31. World Health Organization Informal Working Group on Echinococcosis (1996) Guideline for treatment of cysts and alveolar echinococcosis in human. Bull World Health Organ. Informal Working Group on Echinococcosis 74:231–242Google Scholar
  32. World Health Organization Informal Working Group of Echinococcosis (2001) Puncture, aspiration, injection, re-aspiration. An option for the treatment of cystic echinococcosis. World Health Organization, Geneva, Switzerland, pp 1–40Google Scholar
  33. Xiao SH, You JQ, Yang YQ, Guo HF, Zhang CW, Chai JJ, Zhang WL (1988) Histological alterations and drug concentrations in endocysts and cysts fluid of hydatid cysts harboring in mice treated with praziquantel. Acta Pharmacol Sin 9:461–464Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Laura Ceballos
    • 1
    • 3
    Email author
  • Celina Elissondo
    • 2
    • 3
  • Laura Moreno
    • 1
    • 3
  • Marcela Dopchiz
    • 2
    • 3
  • Sergio Sánchez Bruni
    • 1
    • 3
  • Guillermo Denegri
    • 2
    • 3
  • Luis Alvarez
    • 1
    • 3
  • Carlos Lanusse
    • 1
    • 3
  1. 1.Departamento de Fisiopatología, Laboratorio de FarmacologíaFacultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Campus UniversitarioTandilArgentina
  2. 2.Departamento de Biología, Laboratorio de Zoonosis ParasitariasFacultad de Ciencias Exactas y Naturales, Universidad Nacional de Mar del Plata (UNMdP)Mar del PlataArgentina
  3. 3.Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)Buenos AiresArgentina

Personalised recommendations